Development of a gene/drug dual delivery system for brain tumor therapy: Potent inhibition via RNA interference and synergistic effects

Biomaterials

Volumn 34, Issue 30, 2013, Pages 7483-7494

  Lei, Chenlu ^a   Cui, Yanna ^a   Zheng, Lin ^b   Kah Hoe Chow, Pierce ^c,d   Wang, Chi Hwa ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Drug gene delivery; Intracranial glioblastoma; Microfiber; MMPs; RNA interference

Indexed keywords

DRUG/GENE DELIVERY; GLIOBLASTOMAS; MICRO-FIBER; MMPS; RNA INTERFERENCE;

BRAIN; CHEMOTHERAPY; DRUG DELIVERY; ENZYME INHIBITION; GENE TRANSFER; NANOPARTICLES; RNA;

TUMORS;

GELATINASE A; NANOPARTICLE; PACLITAXEL; PLASMID DNA; POLYETHYLENEIMINE;

ANGIOGENESIS; ANGIOGENIC GENE THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG IMPLANT; GENE DELIVERY SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SUSTAINED DRUG RELEASE; TUMOR XENOGRAFT;

DRUG/GENE DELIVERY; INTRACRANIAL GLIOBLASTOMA; MICROFIBER; MMPS; RNA INTERFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DNA; DOWN-REGULATION; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMPLANTS, EXPERIMENTAL; LUMINESCENT MEASUREMENTS; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; PLASMIDS; POLYETHYLENEIMINE; RNA INTERFERENCE;

MUS MUSCULUS;

EID: 84880512700     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.06.010     Document Type: Article

References (35)

1. Wong E.T. Tumor growth, invasion, and angiogenesis in malignant gliomas. JNeurooncol 2006, 77:295-296.
2. Chiocca E.A., Broaddus W.C., Gillies G.T., Visted T., Lamfers M.L.M. Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology. JNeuro-Oncol 2004, 69:101-117.
3. Folkman J. Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med 1975, 82(1):96-100.
4. Skobe M., Rockwell R., Goldstein N., Vosseler S., Fusenig N.E. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997, 3:1222-1227.
5. Woessner J.F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991, 5:2145-2154.
6. Curran S., Murray G.I. Matrix metalloproteinases: molecular aspects of their roles in tumor invasion and metastasis. Eur J Cancer 2000, 36:1621-1630.
7. Westermarck J., Kähäri V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999, 13:781-792.
8. Nakano A., Tani E., Miyazaki K., Yamamoto Y., Furuyama J. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. JNeurosurg 1995, 83:298-307.
9. Sawaya R.E., Yamamoto M., Gokaslan Z.L., Wang S.W., Mohanam S., Fuller G.N., et al. Expression and localization of 72kDa type IV collagenase (MMP-2) in human malignant gliomas invivo. Clin Exp Metastasis 1996, 14:35-42.
10. Yong V.W., Power C., Forsyth P., Edwards D.R. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001, 2:502-511.
11. Rutka J.T., Matsuzawa K., Hubbard S.L., Fukuyama K., Becker L.E., StetlerStevenson W., et al. Expression of TIMP-1, TIMP-2, 72- and 92-kDa type IV collagenase transcripts in human astrocytoma cell lines: correlation with astrocytoma cell invasiveness. Int J Oncol 1995, 6:877-884.
12. Nakagawa T., Kubota T., Kabuto M., Fujimoto N., Okada Y. Secretion of matrix metalloproteinase-2 (72 kD gelatinase/type IV collagenase=gelatinase A) by malignant human glioma cell lines: implications for the growth and cellular invasion of the extracellular matrix. JNeurooncol 1996, 28:13-24.
13. Uhm J.H., Dooley N.P., Villemure J.G., Yong V.W. Glioma invasion invitro: regulation by matrix metalloproteinase-2 and protein kinase C. Clin Exp Metastasis 1996, 14:421-433.
14. Forsyth P.A., Laing T.D., Gibson A.W., Rewcastle N.B., Brasher P., Sutherland G., et al. High levels of gelatinase-B and active gelatinase-A in metastatic glioblastoma. JNeurooncol 1998, 36:21-29.
15. Lampert K., Machein U., Machein M.R., Conca W., Peter H.H., Volk B. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Pathol 1998, 153:429-437.
16. Chintala S.K., Tonn J.C., Rao J.S. Matrix metalloproteinases and their biological function in human gliomas. Int J Dev Neurosci 1999, 17:495-502.
17. Kodera T., Nakagawa T., Kubota T., Sato K., Kobayashi H. The expression and activation of matrix etalloproteinase-2 in rat brain after implantation of C6 rat glioma cells. JNeuro-Oncol 2000, 46:105-114.
18. Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., et al. Amatrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994, 370:61-65.
19. Brooks P.C., Stromblad S., Sanders L.C., von Schalscha T.L., Aimes R.T., Stetler-Stevenson W.G., et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 1996, 85:683-693.
20. Tonn J.C., Kerkau S., Hanke A., Bouterfa H., Mueller J.G., Wagner S., et al. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas invitro. Int J Cancer 1999, 80:764-772.
21. Watanabe K., Yoshida D., Noha M., Teramoto A. Suppression of matrix metalloproteinase-2 and -9 mediated invasiveness by a novel matrix metalloproteinase inhibitor, BE16627B. JNeurooncol 2001, 52:1-9.
22. Nakada M., Kita D., Futami K., Yamashita J., Fujimoto N., Sato H., et al. Roles of membrane type 1 matrix metalloproteinase and tissue inhibitor of metalloproteinases 2 in invasion and dissemination of human malignant glioma. JNeurosurg 2001, 94:464-473.
23. Groves M.D., Puduvalli V.K., Hess K.R., Jaeckle K.A., Peterson P., Yung W.K.A., et al. Phase II trial of temozolomide plus the matrix metalloprotease inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. JClin Oncol 2002, 20:1383-1388.
24. Levin V., Phuphanich S., Glantz M.J. Randomized phase II study of temozolomide (TMZ) with and without the matrix metalloprotease (MMP) inhibitor prinomastat in patients (pts) with glioblastoma multiforme (GBM) following best surgery and radiation therapy. Proceed ASCO 2002, 21:26a.
25. Zamore P.D. RNA interference: listening to the sound of silence. Nat Struct Biol 2001, 8:746-750.
26. Sioud M. On the delivery of small interfering RNAs into mammalian cells. Expert Opin Drug Deliv 2005, 2:639-651.
27. Zhang S., Zhao B., Jiang H., Wang B., Ma B. Cationic lipids and polymers mediated vectors for delivery of siRNA. JControl Release 2007, 123:1-10.
28. Bookout A.L., Cummins C.L., Kramer M.F., Pesola J.M., Manelsdorf D.J. High-throughput real-time quantitative reverse transcription PCR. Current protocols in molecular biology 2006, John Wiley & Sons, Unit 15.8. G. Taylor (Ed.).
29. Ranganath S.H., Fu Y., Arifin D.Y., Kee I., Zheng L., Lee H.S., et al. The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice. Biomaterials 2010, 31:5199-5207.
30. Senn C., Hangartner C., Moes S. Central administration of small interfering RNAs in rats: a comparison with antisense oligonucleotides. Eur J Pharmacol 2005, 522(1-3):30-37.
31. Nakajima H., Kubo T., Semi Y. Arapid, neuron-selective, invivo knockdown following a single intracerebroventricular injection of a novel chemically modified siRNA in the adult rat brain. JBiotechnol 2012, 157(2):326-333.
32. Uno Y., Piao W., Miyata K. High-density lipoprotein facilitates invivo delivery of alpha-tocopherol-conjugated short-interfering RNA to the brain. Hum Gene Ther 2011, 22(6):711-719.
33. Naraharisetti P.K., Ong Y.S.B., Xie J.W., Lee K.Y.T., Wang C.H., Sahinidis N.V. Invivo performance of implantable biodegradable preparations delivering paclitaxel and etanidazole for the treatment of glioma. Biomaterials 2007, 28(5):886-894.
34. Kim G.Y., Tyler B.M., Tupper M.M., Karp J.M., Langer R.S., Brem H. Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model. JControlRelease 2007, 123:172-178.
35. Nie H., Fu Y., Wang C.H. Paclitaxel and suramin-loaded core/shell microspheres in the treatment of brain tumors. Biomaterials 2010, 31(33):8732-8740.